Dexmedetomidine an adjuvant to ropivacaine in femoral nerve block: a randomized double blind prospective study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006646

Enrollment

Unknown

Registered

2015-06-24

Start date

2015-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior cruciate ligament rupture

Interventions

D?:add dexmedetomidine 100ug

Control:ropivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Eighty ASA I-II patients scheduled for elective reconstruction of anterior cruciate ligament surgery were divided into two equal groups in a randomized double blind fashion.

Exclusion criteria

Exclusion criteria: Patient refused; femoral nerve injury with serious cardiovascular disease; allergic to the drugs used in the test; puncture site infection; comprehension obstacles (unable to understand the pain assessment method); recent opioid drugs.

Design outcomes

Primary

Measure	Time frame
VAS score;	—

Countries

China

Contacts

Public ContactMin Li

liminanesth@aliyun.com+86 15611908799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026